Targeting mitochondria is a promising strategy for precision tumor therapy, yet ligand-free mitochondrial drug delivery remains challenging. Here, we report a minimalist, intrinsically mitochondria-targeting noncanonical tetrapeptide, X-GNNpY, comprising one glycine, two (S)-2-amino-3-(naphthalen-1-yl)-propanoic acid residues (N), and one phosphorylated tyrosine (pY). Without external targeting ligands, X-GNNpY selectively accumulates in tumor-cell mitochondria through enzyme-instructed self-assembly. Conjugating chlorambucil (CLB) yields CLB-GNNpY, which efficiently redirects CLB to mitochondria. CLB-GNNpY exhibits good cellular selectivity, induces mitochondrial stress and immunogenic cell death, promotes M1-like macrophage polarization, and markedly enhances antitumor phagocytosis. This proof-of-concept study establishes noncanonical peptide self-assembly as a ligand-free supramolecular strategy for mitochondrial drug delivery and immune modulation in tumor therapy.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: